

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE**  
**Recommendations Summary**  
**May 10, 2017**

---

**In Attendance:**

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Robert Rohloff, M.D.	Yes - left @ 12:00 p.m.
4	Catherine Decker, Pharm.D.	Yes - arrived @ 9:40 a.m.
6	John Fangman, M.D.	Yes
7	Kevin Izard, M.D.	Yes - arrived @ 10:00 a.m.
8	Steve Maike, RPh	Yes
9	William E. Raduege, M.D.	Yes
10	Pat Towers	Yes
11	Alicia Walker, Pharm.D.	Yes
12	Michael Witkovsky, M.D.	Yes - arrived @ 9:25 a.m.

## MAY 2017 THERAPEUTIC DRUG CLASS

ACNE AGENTS, TOPICAL  
ANALGESICS, MISCELLANEOUS  
ANALGESICS, NARCOTICS LONG  
ANALGESICS, NARCOTICS SHORT  
ANDROGENIC AGENTS  
ANGIOTENSIN MODULATOR COMBINATIONS  
ANGIOTENSIN MODULATORS  
ANTIBIOTICS, GI  
ANTIBIOTICS, INHALED  
ANTIBIOTICS, TOPICAL  
ANTIBIOTICS, VAGINAL  
ANTICOAGULANTS  
ANTIEMETIC/ANTIVERTIGO AGENTS  
ANTIFUNGALS, ORAL  
ANTIFUNGALS, TOPICAL  
ANTIMIGRAINE AGENTS  
ANTIPARTASITICS, TOPICAL  
ANTIVIRALS, ORAL  
ANTIVIRALS, TOPICAL  
BETA BLOCKERS  
BLADDER RELAXANT PREPARATIONS  
BONE RESORPTION SUPPRESSION AND RELATED AGENTS  
BPH TREATMENTS  
CALCIUM CHANNEL BLOCKERS  
CEPHALOSPORINS AND RELATED AGENTS  
FLUOROQUINOLONES, ORAL  
GI MOTILITY, CHRONIC  
GROWTH HORMONE  
H. PYLORI TREATMENT  
HEPATITIS B AGENTS  
HEPATITIS C AGENTS  
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS  
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS  
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS  
HYPOGLYCEMICS, MEGLITINIDES  
HYPOGLYCEMICS, OTHER  
HYPOGLYCEMICS, SULFONYLUREAS  
HYPOGLYCEMICS, TZD  
LIPOTROPICS, OTHER  
LIPOTROPICS, STATINS  
MACROLIDES/KETOLIDES  
MULTIPLE SCLEROSIS AGENTS  
OPIATE DEPENDENCE TREATMENTS  
PAH AGENTS, ORAL AND INHALED  
PANCREATIC ENZYMES  
PENICILLINS  
PHOSPHATE BINDERS  
PLATELET AGGREGATION INHIBITORS  
PROTON PUMP INHIBITORS  
SKELETAL MUSCLE RELAXANTS  
TETRACYCLINES  
ULCERATIVE COLITIS AGENTS

## **Recommendations Summary:**

The following drug classes presented for review had no recommended changes since the November 11, 2016 Wisconsin Medicaid Pharmacy PA Advisory Committee (PAC). The PAC had no additional discussion regarding these drug classes.

Drug Classes included in the committee block vote:

- ANALGESICS, MISCELLANEOUS
  - ANDROGENIC AGENTS
  - ANTIBIOTICS, INHALED
  - ANTIBIOTICS, TOPICAL
  - ANTICOAGULANTS
  - ANTIFUNGALS, ORAL
  - ANTIFUNGALS, TOPICAL
  - ANTIVIRALS, TOPICAL
  - BETA BLOCKERS
  - BONE RESORPTION SUPPRESSION AND RELATED AGENTS
  - CALCIUM CHANNEL BLOCKERS
  - CEPHALOSPORINS AND RELATED AGENTS
  - FLUOROQUINOLONES
  - H. PYLORI TREATMENT
  - HEPATITIS C AGENTS
  - HYPOGLYCEMICS, MEGLITINIDES
  - HYPOGLYCEMICS, METFORMINS
  - HYPOGLYCEMICS, SULFONYLUREAS
  - HYPOGLYCEMICS, TZD
  - PANCREATIC ENZYMES
  - PENICILLINS
  - PHOSPHATE BINDERS
  - PROTON PUMP INHIBITORS
  - SKELETAL MUSCLE RELAXANTS
- 
- Discussion: John Fangman thanked the Department for its efforts both in general and specifically with the Hepatitis C Agents class. He commended the Department for being responsive to the needs of prescribers and members, ensuring members have access to clinically sound treatment with a fiscally responsible approach.
  - Kevin Izard made a motion to accept staff recommendations as presented.
    - Second - Roseanne Barber
    - All members were in favor of the motion
    - Motion passes

ACNE AGENTS, TOPICAL							
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS	
VELTIN (TOPICAL)	0.0%	OFF	No				
BENZAFLIN W/PUMP (TOPICAL)	0.0%	OFF	No				
BENZOYL PEROXIDE LOTION OTC (TOPICAL)	0.1%	ON	Yes-Gen				
AZELEX (TOPICAL)	1.5%	ON	Yes				
RETIN-A GEL (TOPICAL)	3.2%	ON	Yes				
BENZOYL PEROXIDE 5% WASH OTC (TOPICAL)	4.0%	ON	Yes-Gen				
TAZORAC GEL (TOPICAL)	0.2%	OFF	No				
ONEXTON W/PUMP (TOPICAL)	0.0%	OFF	No				
EPIDUO (TOPICAL)	8.3%	ON	Yes				
TAZORAC CREAM (TOPICAL)	0.3%	OFF	No				
ACANYA W/PUMP (TOPICAL)	0.0%	OFF	No				
DIFFERIN LOTION (TOPICAL)	0.2%	ON	Yes				
RETIN-A CREAM (TOPICAL)	13.6%	ON	Yes				
DIFFERIN CREAM (TOPICAL)	4.0%	ON	Yes				
BENZOYL PEROXIDE GEL OTC (TOPICAL)	9.9%	ON	Yes-Gen				
DIFFERIN GEL (TOPICAL)	6.5%	ON	Yes				
DIFFERIN GEL PUMP (TOPICAL)	2.1%	ON	Yes				
BENZOYL PEROXIDE 10% WASH OTC (TOPICAL)	3.1%	ON	Yes-Gen				
ZIANA (TOPICAL)	0.0%	OFF	No				
RETIN-A MICRO 0.08% PUMP (TOPICAL)	0.0%	OFF	No				
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.1%	OFF	No-Gen				
ERYTHROMYCIN GEL (AG) (TOPICAL)	0.0%	OFF	No				
BENZAFLIN (TOPICAL)	0.0%	OFF	No				
AVITA GEL (TOPICAL)	0.0%	OFF	No				
BENZOYL PEROXIDE CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
ERYTHROMYCIN SOLUTION (TOPICAL)	1.2%	ON	Yes-Gen				
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	9.2%	ON	Yes-Gen				
EPIDUO FORTE GEL W/PUMP (TOPICAL)	0.1%	OFF	No				
AVITA CREAM (TOPICAL)	0.0%	OFF	No				
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% (AG) (TOPICAL)	0.0%	OFF	No-Gen				
ACZONE GEL (TOPICAL)	0.3%	OFF	No				
SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL)	0.0%	OFF	No-Gen				
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	1.0%	ON	Yes-Gen				
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	28.7%	ON	Yes-Gen				
FABIOR (TOPICAL)	0.0%	OFF	No				
SULFACETAMIDE SUSPENSION (TOPICAL)	0.1%	OFF	No-Gen				
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% PUMP (AG) (TOPICAL)	0.0%	OFF	No-Gen				
SULFACETAMIDE SODIUM/SULFUR (TOPICAL)	0.0%	ON	No-Gen				
TRETINOIN GEL (AVITA, RETIN-A) (TOPICAL)	0.1%	OFF	No-Gen				
TRETINOIN CREAM (TOPICAL)	0.7%	OFF	No-Gen				
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	0.6%	OFF	No-Gen				
SULFACETAMIDE CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)	0.1%	OFF	No-Gen				
ERYTHROMYCIN GEL (TOPICAL)	0.1%	OFF	No-Gen				
ADAPALENE GEL (AG) (TOPICAL)	0.0%	OFF	No-Gen				
ADAPALENE GEL (TOPICAL)	0.1%	OFF	No-Gen				
BENZOYL PEROXIDE FOAM (TOPICAL)	0.0%	OFF	No-Gen				
ADAPALENE CREAM (TOPICAL)	0.0%	OFF	No-Gen				
BENZEPRO CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
KLARON (TOPICAL)	0.0%	OFF	No				
BENZOYL PEROXIDE MICROSPHERES CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
ADAPALENE GEL PUMP (AG) (TOPICAL)	0.0%	NR	No-Gen				
ADAPALENE GEL PUMP (TOPICAL)	0.0%	NR	No-Gen				
TRETINOIN GEL (ATRALIN) (TOPICAL)	0.0%	OFF	No-Gen				
SULFACETAMIDE SODIUM/SULFUR CREAM (TOPICAL)	0.0%	OFF	No-Gen				
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
CLINDAMYCIN / BENZOYL PEROXIDE (BENZAFLIN) (TOPICAL)	0.1%	OFF	No-Gen				
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	0.0%	OFF	No-Gen				
ACZONE GEL W/PUMP (TOPICAL)	0.1%	NR	No				
CLINDAMYCIN / BENZOYL PEROXIDE (BENZAFLIN) W/PUMP (TOPICAL)	0.0%	NR	No-Gen				
BENZAMYCIN (TOPICAL)	0.0%	OFF	No				
BENZOYL PEROXIDE GEL (TOPICAL)	0.0%	OFF	No-Gen				
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% (TOPICAL)	0.1%	OFF	No-Gen				
ATRALIN (TOPICAL)	0.0%	OFF	No				
RETIN-A MICRO 0.04%, 0.1% (TOPICAL)	0.1%	OFF	No				
SULFACETAMIDE SODIUM/SULFUR LOTION (TOPICAL)	0.0%	OFF	No-Gen				
AVAR FOAM (TOPICAL)	0.0%	OFF	No				
OVACE PLUS FOAM (TOPICAL)	0.0%	OFF	No				
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	0.0%	OFF	No-Gen				
PLEXION CLEANSER (TOPICAL)	0.0%	OFF	No				
RETIN-A MICRO 0.04%, 0.1% PUMP (TOPICAL)	0.0%	OFF	No				
OVACE PLUS WASH (TOPICAL)	0.0%	OFF	No				
BP 10-1 (TOPICAL)	0.0%	OFF	No-Gen				
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% PUMP (TOPICAL)	0.0%	OFF	No-Gen				
AVAR CLEANSER (TOPICAL)	0.0%	OFF	No-Gen				
CLINDAMYCIN / TRETINOIN (TOPICAL)	0.0%	NR	No-Gen				
CLINDAGEL (TOPICAL)	0.0%	OFF	No				

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Alicia Walker
  - All members were in favor of the motion
  - Motion passes

ANALGESICS, NARCOTICS LONG						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHADONE SOL TABLET (ORAL)	0.0%	ON	Yes			
METHADONE TABLET (ORAL)	9.6%	OFF	No-Gen			
NUCYNTA ER (ORAL)	1.0%	OFF	No			
TRAMADOL ER (ULTRAM ER) (ORAL)	0.5%	OFF	Yes-Gen			
METHADONE SOLUTION (ORAL)	0.2%	OFF	No-Gen			
MORPHINE ER TABLET (ORAL)	37.5%	ON	Yes-Gen			
TRAMADOL ER (RYZOLT) (ORAL)	0.0%	OFF	No-Gen			
HYSINGLA ER (ORAL)	2.5%	ON	Yes			
EMBEDA (ORAL)	0.2%	OFF	Yes			
FENTANYL (TRANSDERM)	19.5%	ON	Yes-Gen			
BUTRANS (TRANSDERM)	7.1%	ON	Yes			
KADIAN (ORAL)	1.3%	ON	Yes			
METHADONE CONC (ORAL)	0.0%	ON	Yes-Gen			
OPANA ER (ORAL)	0.9%	OFF	No			
TRAMADOL ER (CONZIP) (AG) (ORAL)	0.0%	OFF	No-Gen			
OXYCONTIN (ORAL)	17.2%	OFF	No			
MORPHINE ER CAPSULE (AVINZA) (ORAL)	0.0%	OFF	No-Gen			
ZOXYDOL ER (ORAL)	0.1%	OFF	No			
BELBUCA (BUCCAL)	0.1%	OFF	No			
MORPHINE ER CAPSULE (KADIAN) (ORAL)	0.0%	OFF	No-Gen			
XTAMPZA ER (ORAL)	0.0%	NR	No			
CONZIP (ORAL)	0.0%	OFF	No			
OXYCODONE ER (AG) (ORAL)	1.6%	NR	No-Gen			
FENTANYL (37.5, 62.5, 87.5 MG) (TRANSDERM)	0.0%	OFF	No-Gen			
OXYMORPHONE ER (ORAL)	0.4%	OFF	No-Gen			
HYDROMORPHONE ER (AG) (ORAL)	0.0%	OFF	No-Gen			
HYDROMORPHONE ER (ORAL)	0.2%	OFF	No-Gen			
EXALGO (ORAL)	0.1%	OFF	No			

- Discussion: Rachel Currans-Henry stated that methadone dosage forms for pain were designated as non-preferred in 2016, and since that change, utilization of methadone has decreased by approximately thirty percent.
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - Pat Towers
  - All members were in favor of the motion
  - Motion passes

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
MEPERIDINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
TRAMADOL (ORAL)	21.6%	ON	Yes-Gen			
APAP / CODEINE ELIXIR (ORAL)	0.3%	ON	Yes-Gen			
APAP / CODEINE TABLET (ORAL)	6.5%	ON	Yes-Gen			
HYDROCODONE / APAP TABLET (ORAL)	24.6%	ON	Yes-Gen			
MORPHINE IR TABLET (ORAL)	0.9%	ON	Yes-Gen			
MORPHINE SOLUTION (ORAL)	0.1%	ON	Yes-Gen			
HYDROMORPHONE TABLET (ORAL)	0.8%	ON	Yes-Gen			
MEPERIDINE TABLET (ORAL)	0.0%	OFF	No-Gen			
MORPHINE CONC SOLUTION (ORAL)	0.1%	ON	Yes-Gen			
OXYCODONE TABLET (ORAL)	24.1%	ON	Yes-Gen			
HYDROCODONE / IBUPROFEN (ORAL)	0.3%	ON	Yes-Gen			
NUCYNTA (ORAL)	0.1%	OFF	No			
OXYCODONE / APAP TABLET (ORAL)	18.7%	ON	Yes-Gen			
CODEINE (ORAL)	0.1%	ON	No-Gen			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Gen			
OXYCODONE SOLUTION (ORAL)	0.9%	ON	Yes-Gen			
OXYCODONE / ASA (ORAL)	0.0%	OFF	No-Gen			
IBUDONE (ORAL)	0.0%	OFF	No-Gen			
BUTORPHANOL TARTRATE (NASAL)	0.0%	OFF	No-Gen			
LORTAB (ORAL)	0.0%	OFF	No-Gen			
DIHYDROCODEINE / ASA / CAFFEINE (AG) (ORAL)	0.0%	OFF	No-Gen			
HYCET (ORAL)	0.0%	OFF	No-Gen			
HYDROCODONE / APAP SOLUTION (ORAL)	0.5%	ON	Yes-Gen			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	OFF	No-Gen			
OXYCODONE / APAP SOLUTION (ORAL)	0.0%	OFF	No-Gen			
HYDROMORPHONE LIQUID (ORAL)	0.0%	OFF	No-Gen			
BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL)	0.1%	OFF	No-Gen			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Gen			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	0.0%	OFF	No-Gen			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.0%	OFF	No-Gen			
REPREXAIN (ORAL)	0.0%	OFF	No-Gen			
CARISOPRODOL COMPOUND-CODEINE (ORAL)	0.0%	OFF	No-Gen			
XARTEMIS XR (ORAL)	0.0%	OFF	No			
OXYCODONE CAPSULE (ORAL)	0.0%	OFF	No-Gen			
ZAMICET (ORAL)	0.0%	OFF	No-Gen			
MORPHINE SUPPOSITORIES (RECTAL)	0.0%	ON	Yes-Gen			
NORCO (ORAL)	0.0%	ON	No-Gen			
OXYMORPHONE (ORAL)	0.1%	OFF	No-Gen			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Gen			
FIORICET / CODEINE (ORAL)	0.0%	OFF	No-Gen			
OXYCODONE CONC (ORAL)	0.0%	OFF	No-Gen			
FENTORA (BUCCAL)	0.0%	OFF	No			
CAPITAL W-CODEINE (ORAL)	0.0%	ON	No-Gen			
PRIMLEV (ORAL)	0.0%	OFF	No-Gen			
FENTANYL (BUCCAL)	0.0%	OFF	No-Gen			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Gen			
LAZANDA (NASAL)	0.0%	OFF	No			
SUBSYS (SUBLINGUAL)	0.0%	OFF	No			

- Discussion: Rachel Currans-Henry stated that the recommendation to non-prefer codeine is based on the population being served and safety concerns when used to treat children. The Wisconsin Medicaid Drug Utilization Review Committee is reviewing opiate use by children less than 18 years old, focusing specifically on codeine and Tramadol.
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Catherine Decker
  - All members were in favor of the motion
  - Motion passes

ANGIOTENSIN MODULATOR COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TARKA (ORAL)	0.3%	OFF	No			
AMLODIPINE / VALSARTAN (AG) (ORAL)	9.6%	ON	Yes-Gen			
TRIBENZOR (ORAL)	23.4%	ON	Yes			
EXFORGE HCT (ORAL)	9.6%	ON	Yes			
AMLODIPINE / BENAZEPRIL (ORAL)	10.4%	ON	Yes-Gen			
AZOR (ORAL)	32.7%	ON	Yes			
TWYNSTA (ORAL)	0.0%	OFF	No			
AMLODIPINE / VALSARTAN (ORAL)	2.2%	ON	Yes-Gen			
AMLODIPINE / OLMESARTAN (AG) (ORAL)	1.6%	NR	No-Gen			
AMLODIPINE / VALSARTAN / HCTZ (AG) (ORAL)	0.0%	OFF	No-Gen			
AMLODIPINE / OLMESARTAN / HCTZ (AG) (ORAL)	0.8%	NR	No-Gen			
PRESTALIA (ORAL)	0.0%	OFF	No			
BYVALSON (ORAL)	0.0%	NR	No			
TRANDOLAPRIL / VERAPAMIL (AG) (ORAL)	0.0%	OFF	No-Gen			
AMLODIPINE / VALSARTAN / HCTZ (ORAL)	0.0%	OFF	No-Gen			
TELMISARTAN / AMLODIPINE (ORAL)	0.1%	OFF	No-Gen			
AMLODIPINE / OLMESARTAN / HCTZ (ORAL)	6.5%	NR	No-Gen			
AMLODIPINE / OLMESARTAN (ORAL)	2.9%	NR	No-Gen			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second - Steve Maike
  - All members were in favor of the motion
  - Motion passes

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LISINOPRIL HCTZ (ORAL)	10.5%	ON	Yes-Gen			
ENALAPRIL HCTZ (ORAL)	0.2%	ON	Yes-Gen			
QUINAPRIL HCTZ (ORAL)	0.0%	OFF	No-Gen			
MOEXIPRIL HCTZ (ORAL)	0.0%	OFF	No-Gen			
BENAZEPRIL HCTZ (ORAL)	0.0%	OFF	No-Gen			
FOSINOPRIL HCTZ (ORAL)	0.0%	OFF	No-Gen			
CAPTROPIL HCTZ (ORAL)	0.0%	OFF	No-Gen			
LISINOPRIL (ORAL)	47.5%	ON	Yes-Gen			
BENAZEPRIL (ORAL)	2.5%	ON	Yes-Gen			
RAMIPRIL (ORAL)	0.3%	ON	Yes-Gen			
FOSINOPRIL (ORAL)	0.1%	ON	Yes-Gen			
QUINAPRIL (ORAL)	0.0%	OFF	No-Gen			
PERINDOPRIL (ORAL)	0.0%	OFF	No-Gen			
ENALAPRIL (ORAL)	4.1%	ON	Yes-Gen			
TRANDOLAPRIL (ORAL)	0.0%	OFF	No-Gen			
QBRELIS SOLUTION (ORAL)	0.0%	NR	No			
MOEXIPRIL (ORAL)	0.0%	OFF	No-Gen			
CAPTROPIL (ORAL)	0.3%	ON	Yes-Gen			
EPANED KIT (ORAL)	0.4%	OFF	No			
EPANED SOLUTION (ORAL)	0.0%	NR	No			
BENICAR (ORAL)	0.1%	OFF	No			
MICARDIS (ORAL)	0.0%	OFF	No			
EDARBI (ORAL)	0.0%	OFF	No			
LOSARTAN (ORAL)	20.6%	ON	Yes-Gen			
IRBESARTAN (ORAL)	0.1%	OFF	No-Gen			
VALSARTAN (AG) (ORAL)	0.1%	ON	Yes-Gen			
VALSARTAN (ORAL)	5.5%	ON	Yes-Gen			
CANDESARTAN (AG) (ORAL)	0.0%	OFF	No-Gen			
TELMISARTAN (AG) (ORAL)	0.0%	OFF	No-Gen			
TELMISARTAN (ORAL)	0.0%	OFF	No-Gen			
CANDESARTAN (ORAL)	0.0%	OFF	No-Gen			
EPROSARTAN (ORAL)	0.0%	OFF	No-Gen			
OLMESARTAN (AG) (ORAL)	0.0%	NR	No-Gen			
OLMESARTAN HCTZ (AG) (ORAL)	0.0%	NR	No-Gen			
OLMESARTAN HCTZ (ORAL)	0.0%	NR	No-Gen			
OLMESARTAN (ORAL)	0.0%	NR	No-Gen			
ENTRESTO (ORAL)	0.1%	OFF	No			
MICARDIS HCT (ORAL)	0.0%	OFF	No			
EDARBYCLOR (ORAL)	0.0%	OFF	No			
LOSARTAN HCTZ (ORAL)	5.7%	ON	Yes-Gen			
IRBESARTAN HCTZ (ORAL)	0.0%	OFF	No-Gen			
BENICAR HCT (ORAL)	0.1%	OFF	No			
VALSARTAN HCTZ (ORAL)	1.4%	ON	Yes-Gen			
TELMISARTAN HCTZ (AG) (ORAL)	0.0%	OFF	No-Gen			
CANDESARTAN HCTZ (ORAL)	0.0%	OFF	No-Gen			
TELMISARTAN HCTZ (ORAL)	0.0%	OFF	No-Gen			
TEKTURNAL HCT (ORAL)	0.0%	OFF	No			
TEKTURNAL (ORAL)	0.0%	OFF	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - Pat Towers
  - All members were in favor of the motion
  - Motion passes



ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE TABLET (ORAL)	92.9%	ON	Yes-Gen			
NEOMYCIN (ORAL)	0.7%	ON	Yes-Gen			
TINIDAZOLE (ORAL)	0.2%	OFF	Yes-Gen			
METRONIDAZOLE CAPSULE (ORAL)	0.0%	OFF	No-Gen			
TINDAMAX (ORAL)	0.0%	OFF	No			
FLAGYL ER (ORAL)	0.0%	OFF	No			
ALINIA SUSPENSION (ORAL)	0.1%	ON	Yes			
ALINIA TABLET (ORAL)	0.2%	ON	Yes			
VANCOMYCIN CAPSULE (AG) (ORAL)	0.1%	ON	Yes-Gen			
VANCOMYCIN CAPSULE (ORAL)	1.6%	ON	Yes-Gen			
XIFAXAN (ORAL)	4.0%	OFF	Yes			
DIFICID TABLET (ORAL)	0.1%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Steve Maike
  - All members were in favor of the motion
  - Motion passes

ANTIBIOTICS, VAGINAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLEOCIN OVULES (VAGINAL)	3.0%	ON	Yes			
CLINDESSE (VAGINAL)	0.0%	OFF	Yes			
CLINDAMYCIN (VAGINAL)	7.7%	ON	Yes-Gen			
CLEOCIN CREAM (VAGINAL)	0.0%	NR	No			
METRONIDAZOLE (VAGINAL)	84.0%	ON	Yes-Gen			
VANCOMYCIN CAPSULE (VAGINAL)	4.4%	ON	Yes			
METROGEL-VAGINAL (VAGINAL)	0.9%	NR	No			
NUVESSA (VAGINAL)	0.0%	OFF	No			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion passes

ANTIEMETIC/ANTIVERTIGO AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METOCLOPRAMIDE TABLET (ORAL)	10.1%	ON	Yes-Gen			
PROMETHAZINE TABLET (ORAL)	4.9%	ON	Yes-Gen			
PROCHLORPERAZINE (ORAL)	4.8%	ON	Yes-Gen			
PROMETHAZINE SYRUP (ORAL)	2.2%	ON	Yes-Gen			
MECLIZINE OTC (ORAL)	1.3%	ON	Yes-Gen			
ONDANSETRON TABLETS (ORAL)	19.6%	ON	Yes-Gen			
METOCLOPRAMIDE SOLUTION (ORAL)	0.4%	ON	Yes-Gen			
EMEND CAPSULE (ORAL)	0.1%	ON	Yes			
ONDANSETRON ODT (ORAL)	41.9%	ON	Yes-Gen			
MECLIZINE (ORAL)	7.9%	ON	Yes-Gen			
ONDANSETRON SOLUTION (ORAL)	0.4%	ON	Yes-Gen			
TRANSDERM-SCOP (TRANSDERM)	1.8%	ON	Yes			
TRIMETHOBENZAMIDE (ORAL)	0.1%	ON	Yes-Gen			
DICLEGIS (ORAL)	3.5%	ON	Yes			
GRANISETRON (ORAL)	0.0%	OFF	Yes-Gen			
PROCHLORPERAZINE (RECTAL)	0.2%	ON	Yes-Gen			
ZUPLENZ (ORAL)	0.0%	OFF	No			
PROMETHAZINE (RECTAL)	0.5%	ON	Yes-Gen			
PROMETHAZINE 50 MG (RECTAL)	0.0%	ON	Yes-Gen			
EMEND POWDER PACKET (ORAL)	0.0%	NR	No			
ANZEMET (ORAL)	0.0%	OFF	No			
CESAMET (ORAL)	0.0%	OFF	No			
EMEND PACK (ORAL)	0.2%	ON	Yes			
AKYNZEO (ORAL)	0.0%	OFF	No			
METOZOLV ODT (ORAL)	0.0%	OFF	No			
APREPITANT CAPSULE (ORAL)	0.0%	NR	No-Gen			
DRONABINOL (ORAL)	0.0%	ON	No-Gen			
METOCLOPRAMIDE ODT (ORAL)	0.0%	OFF	No-Gen			
APREPITANT PACK (ORAL)	0.0%	NR	No-Gen			
SANCUSO (TRANSDERMAL)	0.0%	OFF	No			
VARUBI (ORAL)	0.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second - Catherine Decker
  - All members were in favor of the motion
  - Motion passes

ANTIMIGRAINE AGENTS, TRIPTANS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOLMITRIPTAN TABLET (AG) (ORAL)	0.0%	OFF	No-Gen			
RELPAX (ORAL)	8.8%	ON	Yes			
SUMATRIPTAN (ORAL)	61.7%	ON	Yes-Gen			
ZOLMITRIPTAN ODT (AG) (ORAL)	0.0%	OFF	No-Gen			
RIZATRIPTAN ODT (ORAL)	6.7%	ON	Yes-Gen			
TREXIMET (ORAL)	0.1%	OFF	No			
RIZATRIPTAN TABLET (ORAL)	12.3%	ON	Yes-Gen			
ZOMIG (NASAL)	0.4%	OFF	No			
NARATRIPTAN (ORAL)	1.0%	OFF	No-Gen			
ZOLMITRIPTAN ODT (ORAL)	0.1%	OFF	No-Gen			
ZOLMITRIPTAN TABLET (ORAL)	0.3%	OFF	No-Gen			
SUMAVEL DOSEPRO (SUBCUTANE.)	0.0%	OFF	No			
SUMATRIPTAN DISP SYRIN (SUBCUTANE.)	0.0%	OFF	Yes-Gen			
ALMOTRIPTAN (ORAL)	0.1%	OFF	No-Gen			
ALMOTRIPTAN (AG) (ORAL)	0.0%	OFF	No-Gen			
SUMATRIPTAN (NASAL)	0.1%	OFF	Yes-Gen			
SUMATRIPTAN VIAL (SUBCUTANE.)	0.0%	OFF	Yes-Gen			
SUMATRIPTAN KIT (SUBCUTANE.)	0.0%	OFF	Yes-Gen			
IMITREX (NASAL)	2.0%	ON	No			
SUMATRIPTAN KIT (SUN) (SUBCUTANE.)	0.0%	OFF	Yes-Gen			
FROVATRIPTAN (ORAL)	0.2%	OFF	No-Gen			
IMITREX VIAL (SUBCUTANE.)	0.2%	ON	No			
ONZETRA XSAIL (NASAL)	0.0%	NR	No			
FROVA (ORAL)	0.1%	OFF	No			
IMITREX KIT (SUBCUTANE.)	5.8%	ON	No			
ZEMBRACE SYMTOUCH (SUBCUTANE.)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes

ANTIPARASITICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PERMETHRIN OTC (TOPICAL)	7.3%	ON	Yes-Gen			
SKLICE (TOPICAL)	32.4%	ON	Yes			
NATROBA (TOPICAL)	3.1%	ON	Yes			
EURAX LOTION (TOPICAL)	0.1%	OFF	No			
EURAX CREAM (TOPICAL)	0.3%	ON	Yes			
PERMETHRIN CREAM (TOPICAL)	56.6%	ON	Yes-Gen			
LINDANE SHAMPOO (TOPICAL)	0.0%	OFF	No-Gen			
SPINOSAD (TOPICAL)	0.0%	OFF	No-Gen			
ULESFIA (TOPICAL)	0.0%	ON	No			
MALATHION BRAND (TOPICAL)	0.2%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR TABLET (ORAL)	22.1%	ON	Yes-Gen			
ACYCLOVIR CAPSULE (ORAL)	3.5%	ON	Yes-Gen			
VALACYCLOVIR (ORAL)	68.9%	ON	Yes-Gen			
FAMCICLOVIR (ORAL)	0.3%	OFF	No-Gen			
ACYCLOVIR SUSPENSION (ORAL)	2.0%	ON	Yes-Gen			
SITAVIG (BUCCAL)	0.0%	OFF	No			
RELENZA (INHALATION)	0.0%	ON	Yes			
TAMIFLU CAPSULE (ORAL)	1.9%	ON	Yes			
OSELTAMIVIR CAPSULE (ORAL)	0.5%	NR	No-Gen			
TAMIFLU SUSPENSION (ORAL)	0.8%	ON	Yes			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Gen			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second - Michael Witkovsky
  - All members were in favor of the motion
  - Motion Passes

BLADDER RELAXANT PREPARATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOVIAZ (ORAL)	7.8%	ON	Yes			
GELNIQUE (TRANSDERM.)	0.1%	OFF	No			
OXYBUTYNIN SYRUP (ORAL)	2.1%	ON	Yes-Gen			
ENABLEX (ORAL)	0.7%	ON	Yes			
VESICARE (ORAL)	30.6%	ON	Yes			
OXYTROL (TRANSDERM.)	0.5%	OFF	No			
OXYBUTYNIN ER (AG) (ORAL)	0.1%	ON	Yes-Gen			
OXYBUTYNIN TABLET (ORAL)	27.3%	ON	Yes-Gen			
OXYBUTYNIN ER (ORAL)	23.9%	ON	Yes-Gen			
TOLTERODINE (ORAL)	0.2%	OFF	No-Gen			
TROSPIUM (ORAL)	0.3%	OFF	No-Gen			
TOLTERODINE ER (AG) (ORAL)	0.6%	OFF	No-Gen			
DARIFENACIN ER (AG) (ORAL)	0.1%	NR	No-Gen			
TOLTERODINE ER (ORAL)	0.4%	OFF	No-Gen			
MYRBETRIQ (ORAL)	4.8%	OFF	No			
TROSPIUM ER (ORAL)	0.2%	OFF	No-Gen			
DARIFENACIN ER (ORAL)	0.0%	NR	No-Gen			
DETROL LA (ORAL)	0.2%	OFF	No			
DETROL (ORAL)	0.0%	OFF	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RAPAFLO (ORAL)	0.3%	OFF	No			
ALFUZOSIN (ORAL)	2.2%	ON	Yes-Gen			
FINASTERIDE (ORAL)	20.2%	ON	Yes-Gen			
TAMSULOSIN (ORAL)	66.9%	ON	Yes-Gen			
TERAZOSIN (ORAL)	9.2%	ON	Yes-Gen			
DUTASTERIDE (ORAL)	0.2%	OFF	Yes-Gen			
CARDURA XL (ORAL)	0.0%	OFF	No			
DOXAZOSIN (ORAL)	0.9%	OFF	No-Gen			
DUTASTERIDE/TAMSULOSIN (ORAL)	0.0%	OFF	No-Gen			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

GI MOTILITY, CHRONIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LOTRONEX (ORAL)	0.5%	ON	Yes			
LINZESS (ORAL)	58.6%	ON	Yes			
MOVANTIK (ORAL)	13.1%	ON	Yes			
AMITIZA (ORAL)	25.6%	ON	Yes			
TRULANCE (ORAL)	0.0%	OFF	No			
VIBERZI (ORAL)	2.1%	ON	No-Gen			
RELISTOR (ORAL)	0.0%	NR	No			
ALOSETRON (ORAL)	0.1%	OFF	No-Gen			
ALOSETRON (AG) (ORAL)	0.1%	OFF	No-Gen			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes

GROWTH HORMONE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GENOTROPIN DISP SYRIN (INJECTION)	0.1%	OFF	Yes			
OMNITROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
ZOMACTON VIAL (INJECTION)	0.0%	OFF	No			
GENOTROPIN CARTRIDGE (INJECTION)	0.0%	OFF	Yes			
NUTROPIN AQ PEN (INJECTION)	9.2%	ON	No			
SAIZEN VIAL (INJECTION)	0.0%	OFF	No			
NORDITROPIN PEN (INJECTION)	90.7%	ON	Yes			
OMNITROPE VIAL (INJECTION)	0.0%	OFF	No			
SAIZEN CARTRIDGE (INJECTION)	0.1%	OFF	No			
SEROSTIM VIAL (INJECTION)	0.0%	OFF	No			
ZORBTIVE VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

HEPATITIS B AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LAMIVUDINE HBV TABLET (ORAL)	0.9%	OFF	Yes-Gen			
LAMIVUDINE HBV TABLET (AG) (ORAL)	0.0%	OFF	Yes-Gen			
BARACLUDE SOLUTION (ORAL)	1.8%	ON	Yes			
TYZEKA (ORAL)	1.8%	ON	Yes			
HEPSERA (ORAL)	5.3%	ON	Yes			
BARACLUDE TABLET (ORAL)	89.4%	ON	Yes			
ADEFOVIR DIPIVOXIL (ORAL)	0.0%	OFF	No-Gen			
VEMLIDY (ORAL)	0.0%	NR	No			
ENTECAVIR TABLET (ORAL)	0.9%	OFF	No-Gen			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLYSET (ORAL)	5.5%	ON	Yes			
ACARBOSE (ORAL)	94.5%	ON	Yes-Gen			
MIGLITOL (ORAL)	0.0%	NR	No-Gen			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second - Alicia Walker
  - All members were in favor of the motion
  - Motion Passes

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KOMBIGLYZE XR (ORAL)	0.2%	OFF	No			
JENTADUETO (ORAL)	2.3%	ON	Yes			
JANUMET (ORAL)	10.3%	ON	Yes			
TRADJENTA (ORAL)	11.8%	ON	Yes			
ONGLYZA (ORAL)	0.7%	OFF	No			
JANUVIA (ORAL)	48.8%	ON	Yes			
JANUMET XR (ORAL)	4.7%	ON	Yes			
JENTADUETO XR (ORAL)	0.0%	NR	No			
ALOGLIPTIN (AG) (ORAL)	0.0%	NR	No-Gen			
ALOGLIPTIN/METFORMIN (AG) (ORAL)	0.0%	NR	No-Gen			
ALOGLIPTIN/PIOGLITAZONE (AG) (ORAL)	0.0%	NR	No-Gen			
KAZANO (ORAL)	0.0%	OFF	No			
NESINA (ORAL)	0.0%	OFF	No			
GLYXAMBI (ORAL)	0.3%	OFF	No			
OSENI (ORAL)	0.0%	OFF	No			
BYETTA PENS (SUBCUTANE.)	3.7%	ON	Yes			
BYDUREON (SUBCUTANE.)	0.7%	ON	Yes			
SYMLIN PENS (SUBCUTANE.)	0.1%	ON	Yes			
BYDUREON PENS (SUBCUTANE.)	10.6%	ON	Yes			
VICTOZA (SUBCUTANE.)	0.7%	OFF	Yes			
TANZEUM (SUBCUTANE.)	5.1%	ON	No			
TRULICITY (SUBCUTANE.)	0.1%	OFF	No			
ADLYXIN (SUBCUTANE.)	0.0%	NR	No			
SOLIQUA (SUBCUTANE.)	0.0%	NR	No			
XULTOPHY (SUBCUTANE.)	0.0%	NR	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - Roseanne Barber
  - All members were in favor of the motion
  - Motion Passes



HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMALOG MIX VIAL (SUBCUTANE.)	0.6%	ON	Yes			
HUMULIN 500 U/M VIAL (SUBCUTANE.)	0.6%	ON	Yes			
HUMULIN 70/30 VIAL OTC (SUBCUTANE.)	1.9%	ON	Yes			
NOVOLOG MIX VIAL (SUBCUTANE.)	0.0%	OFF	Yes			
NOVOLOG MIX PEN (SUBCUTANE.)	0.1%	OFF	Yes			
HUMALOG MIX PEN (SUBCUTANE.)	2.7%	ON	Yes			
HUMULIN VIAL OTC (SUBCUTANE.)	3.5%	ON	Yes			
NOVOLIN VIAL OTC (SUBCUTANE.)	0.0%	OFF	No			
HUMULIN 70/30 PEN OTC (SUBCUTANE.)	2.1%	ON	Yes			
NOVOLIN 70/30 VIAL OTC (SUBCUTANE.)	0.0%	OFF	No			
HUMULIN 500 U/M PEN (SUBCUTANE.)	0.1%	OFF	No			
HUMULIN PEN OTC (SUBCUTANE.)	0.9%	ON	Yes			
LANTUS VIAL (SUBCUTANE.)	10.0%	ON	Yes			
LANTUS SOLOSTAR PEN (SUBCUTANE.)	36.0%	ON	Yes			
LEVEMIR VIAL (SUBCUTANE.)	0.9%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	5.1%	ON	Yes			
BASAGLAR KWIKPEN (SUBCUTANE.)	0.0%	NR	No			
TRESIBA FLEXTOUCH 100 U/ML PEN (SUBCUTANEOUS)	0.0%	OFF	No			
TRESIBA FLEXTOUCH 200 U/ML PEN (SUBCUTANEOUS)	0.0%	OFF	No			
TOUJEO SOLOSTAR PEN (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG VIAL (SUBCUTANE.)	9.4%	ON	Yes			
APIDRA VIAL (SUBCUTANE.)	0.0%	OFF	No			
APIDRA SOLOSTAR PEN (SUB-Q)	0.0%	OFF	No			
NOVOLOG VIAL (SUBCUTANE.)	0.2%	OFF	Yes			
NOVOLOG CARTRIDGE (SUBCUTANE.)	0.0%	OFF	Yes			
NOVOLOG PEN (SUBCUTANE.)	0.2%	OFF	Yes			
HUMALOG CARTRIDGE (SUBCUTANE.)	2.6%	ON	Yes			
HUMALOG PEN (SUBCUTANE.)	22.7%	ON	Yes			
HUMALOG 200 U/ML PEN (SUBCUTANE.)	0.1%	OFF	No			
AFREZZA CARTRIDGE (INHALATION)	0.0%	OFF	No			

- Discussion: Rachel Currans-Henry stated that both pens and vials are available as preferred products.
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second - Steve Maike
  - All members were in favor of the motion
  - Motion Passes

HYPOGLYCEMICS, SGLT2						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FARXIGA (ORAL)	4.2%	OFF	Yes			
INVOKANA (ORAL)	89.5%	ON	Yes			
SYNJARDY (ORAL)	0.2%	OFF	No			
XIGDUO XR (ORAL)	0.3%	OFF	No			
INVOKAMET (ORAL)	3.5%	ON	No			
JARDIANCE (ORAL)	2.3%	OFF	No			
INVOKAMET XR (ORAL)	0.1%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Alicia Walker
  - All members were in favor of the motion
  - Motion Passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WELCHOL TABLET (ORAL)	1.1%	OFF	Yes			
WELCHOL POWDER PACK (ORAL)	0.1%	OFF	Yes			
COLESTIPOL TABLET (ORAL)	3.0%	ON	Yes-Gen			
CHOLESTYRAMINE/ASPARTAME (ORAL)	2.3%	ON	Yes-Gen			
COLESTID GRANULES (ORAL)	0.0%	OFF	No			
COLESTIPOL GRANULES (ORAL)	0.0%	OFF	No-Gen			
CHOLESTYRAMINE/SUCROSE (ORAL)	4.3%	ON	Yes-Gen			
REPATHA PUSHTRONEX (SUBCUTANEOUS)	0.0%	NR	No			
PRALUENT SYRINGE (SUBCUTANEOUS)	0.0%	OFF	No			
PRALUENT PEN (SUBCUTANEOUS)	0.1%	OFF	No			
REPATHA SURECLICK (SUBCUTANEOUS)	0.1%	OFF	No			
REPATHA SYRINGE (SUBCUTANEOUS)	0.0%	OFF	No			
ZETIA (ORAL)	16.0%	ON	Yes			
ANTARA (ORAL)	0.0%	OFF	No			
FENOFIBRATE TABLET (AG) (TRICOR) (ORAL)	0.1%	OFF	Yes-Gen			
GEMFIBROZIL (ORAL)	13.2%	ON	Yes-Gen			
FENOFIBRATE TABLET (TRICOR) (ORAL)	0.1%	OFF	Yes-Gen			
TRICOR (ORAL)	41.8%	ON	No			
FENOFIBRATE CAPSULE (LIPOFEN) (ORAL)	0.0%	OFF	No-Gen			
FENOFIBRIC ACID (FIBRICOR) (ORAL)	0.0%	OFF	No-Gen			
FENOFIBRIC ACID (TRILIPIX) (AG) (ORAL)	0.0%	OFF	Yes-Gen			
FENOFIBRIC ACID (TRILIPIX) (ORAL)	0.0%	OFF	Yes-Gen			
LIPOFEN (ORAL)	0.0%	OFF	No			
FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)	0.4%	OFF	No-Gen			
FENOFIBRATE TABLET (LOFIBRA) (ORAL)	0.6%	OFF	No-Gen			
FENOGLIDE (ORAL)	0.0%	OFF	No			
FENOFIBRATE (ANTARA) (AG) (ORAL)	0.0%	OFF	No-Gen			
FENOFIBRATE (ANTARA) (ORAL)	0.0%	OFF	No-Gen			
TRIGLIDE (ORAL)	0.0%	OFF	No			
OMEGA-3 ACID ETHYL ESTERS (ORAL)	0.8%	OFF	Yes-Gen			
VASCEPA (ORAL)	0.0%	OFF	No			
FENOFIBRATE (FENOGLIDE) (AG) (ORAL)	0.0%	OFF	No-Gen			
EZETIMIBE (ORAL)	1.0%	NR	No-Gen			
TRILIPIX (ORAL)	7.1%	ON	No			
LOVAZA (ORAL)	0.9%	ON	No			
FENOFIBRATE (FENOGLIDE) (ORAL)	0.0%	NR	No-Gen			
KYNAMRO (SUBCUTANE.)	0.0%	OFF	No			
JUXTAPID (ORAL)	0.0%	OFF	No			
NIACIN ER (ORAL)	6.9%	ON	Yes-Gen			
NIACOR (ORAL)	0.1%	ON	Yes-Gen			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	25.9%	ON	Yes-Gen			
VYTORIN (ORAL)	0.1%	OFF	No			
CRESTOR (ORAL)	4.1%	OFF	No			
LOVASTATIN (ORAL)	5.8%	ON	Yes-Gen			
ROSUVASTATIN (ORAL)	0.0%	NR	Yes-Gen			
ATORVASTATIN (ORAL)	51.0%	ON	Yes-Gen			
PRAVASTATIN (ORAL)	12.9%	ON	Yes-Gen			
LESCOL XL (ORAL)	0.0%	OFF	No			
FLUVASTATIN ER (ORAL)	0.0%	OFF	No-Gen			
ALTOPREV (ORAL)	0.0%	OFF	No			
LIVALO (ORAL)	0.1%	OFF	No			
FLUVASTATIN (ORAL)	0.0%	OFF	No-Gen			
FLUVASTATIN ER (AG) (ORAL)	0.0%	OFF	No-Gen			
AMLODIPINE-ATORVASTATIN (ORAL)	0.0%	OFF	No-Gen			
CADUET (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Catherine Decker
  - All members were in favor of the motion
  - Motion Passes

MACROLIDES/KETOLIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZITHROMYCIN TABLET (ORAL)	68.2%	ON	Yes-Gen			
CLARITHROMYCIN TABLET (ORAL)	1.9%	ON	Yes-Gen			
AZITHROMYCIN PACKET (ORAL)	0.3%	ON	Yes-Gen			
ZMAX (ORAL)	0.0%	OFF	No			
AZITHROMYCIN SUSPENSION (ORAL)	28.2%	ON	Yes-Gen			
ERYTHROMYCIN ETHYLSUCCINATE 200 SUSPENSION (AG) (ORAL)	0.0%	NR	Yes-Gen			
PCE (ORAL)	0.0%	ON	Yes-Gen			
ERYTHROMYCIN BASE CAPSULE DR (ORAL)	0.1%	ON	Yes-Gen			
KETEK (ORAL)	0.0%	OFF	No			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	No-Gen			
CLARITHROMYCIN SUSPENSION (ORAL)	0.3%	ON	Yes-Gen			
ERY-TAB (ORAL)	0.4%	ON	Yes-Gen			
E.E.S. 400 TABLET (ORAL)	0.1%	ON	Yes-Gen			
ERYTHROCIN (ORAL)	0.1%	ON	Yes-Gen			
ERYTHROMYCIN BASE TABLET (ORAL)	0.0%	OFF	No-Gen			
E.E.S. 200 SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			
ERYPED 200 SUSPENSION (ORAL)	0.3%	ON	Yes-Gen			
ERYPED 400 SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
COPAXONE 20 MG/ML (SUBCUTANE.)	10.1%	ON	Yes			
AVONEX (INTRAMUSC.)	3.6%	ON	Yes			
AVONEX PEN (INTRAMUSC)	7.9%	ON	Yes			
REBIF (SUBCUTANE.)	3.1%	ON	Yes			
REBIF REBIDOSE PEN INJCTR (SUBCUTANE.)	3.2%	ON	Yes			
BETASERON KIT (SUBCUTANE.)	3.8%	ON	Yes			
AMPYRA (ORAL)	9.9%	OFF	No			
AUBAGIO (ORAL)	13.2%	ON	Yes			
EXTAVIA KIT (SUBCUTANE.)	0.0%	OFF	No			
GILENYA (ORAL)	13.5%	ON	Yes			
EXTAVIA VIAL (SUBCUTANE.)	0.0%	OFF	No			
COPAXONE 40 MG/ML (SUBCUTANE.)	24.5%	ON	Yes			
TECFIDERA (ORAL)	7.3%	OFF	No			
PLEGRIDY (SUBCUTANE.)	0.0%	OFF	No			
GLATIRAMER 20 MG/ML (SUBCUTANE.)	0.0%	OFF	No-Gen			
ZINBRYTA (SUBCUTANE.)	0.0%	NR	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

OPIATE DEPENDENCE TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NALTREXONE (ORAL)	6.9%	ON	Yes-Gen			
NALOXONE SYRINGE (INJECTION)	0.1%	ON	Yes-Gen			
NALOXONE VIAL (INJECTION)	0.1%	ON	Yes-Gen			
EVZIO (INJECTION)	0.0%	OFF	No			
NARCAN SPRAY (NASAL)	3.7%	ON	Yes			
VIVITROL (INTRAMUSC)	7.2%	ON	Yes			
BUPRENORPHINE HCL (SUBLINGUAL)	3.6%	OFF	No-Gen			
SUBOXONE FILM (SUBLINGUAL)	78.3%	ON	Yes			
ZUBSOLV (SUBLINGUAL)	0.1%	OFF	Yes			
BUNAVAIL (BUCCAL)	0.0%	OFF	No			
BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)	0.0%	OFF	No-Gen			

- Discussion: Rachel Currans-Henry stated that the Department received a fair amount of written and oral testimony for this drug class and that a primary goal of this class is to provide diversion from opiate use while members receive treatment for their opiate dependency. Though preferring an additional buprenorphine treatment results in increased costs for the State Medicaid program, increasing access to drugs in this class supports the Department's effort to address the opioid epidemic. Rachel Currans-Henry indicated the prior authorization is required for all buprenorphine treatments in this class, regardless of whether they are preferred or non-preferred.

- Michael Heifetz, Chairman of the Committee and Wisconsin Medicaid Director, acknowledged the many advocates in the audience and indicated that the Committee has to balance cost, access and the needs of members, providers, taxpayers, clinicians, law enforcement and others in addressing the opioid epidemic. Efforts by the Wisconsin Medicaid program are part, but not all, of what is required in this effort.
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

PAH AGENTS, ORAL AND INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VENTAVIS (INHALATION)	0.0%	OFF	No			
TYVASO (INHALATION)	1.3%	OFF	No			
TRACLEER (ORAL)	6.5%	ON	Yes			
LETAIRIS (ORAL)	14.7%	ON	Yes			
OPSUMIT (ORAL)	3.5%	OFF	No			
SILDENAFIL (ORAL)	46.7%	ON	Yes-Gen			
ADCIRCA (ORAL)	17.9%	OFF	Yes			
REVATIO SUSPENSION (ORAL)	0.0%	OFF	No			
ORENITRAM ER (ORAL)	2.0%	OFF	No			
ADEMPAS (ORAL)	4.8%	OFF	No			
UPTRAVI (ORAL)	2.4%	NR	No			
UPTRAVI TABLET DOSE PACK (ORAL)	0.0%	NR	No			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
  - Second - William Raduege
  - All members were in favor of the motion
  - Motion Passes

**PLATELET AGGREGATION INHIBITORS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOPIDOGREL (ORAL)	91.3%	ON	Yes-Gen			
AGGRENOX (ORAL)	4.1%	ON	Yes			
DIPYRIDAMOLE (ORAL)	0.2%	ON	Yes-Gen			
TICLOPIDINE (ORAL)	0.0%	OFF	No-Gen			
BRILINTA (ORAL)	2.9%	OFF	Yes			
YOSPRALA (ORAL)	0.0%	NR	No			
EFFIENT (ORAL)	1.3%	OFF	No			
DURLAZA (ORAL)	0.0%	OFF	No			
ASPIRIN/DIPYRIDAMOLE (AG) (ORAL)	0.0%	NR	No-Gen			
ZONTIVITY (ORAL)	0.0%	OFF	No			
ASPIRIN/DIPYRIDAMOLE (ORAL)	0.0%	NR	No-Gen			

- Discussion:None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second - Pat Towers
  - All members were in favor of the motion
  - Motion Passes

**TETRACYCLINES**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOXYCYCLINE HYCLATE CAPSULE (AG) (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL)	0.0%	ON	Yes-Gen			
VIBRAMYCIN SYRUP (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL)	0.3%	ON	Yes-Gen			
DORYX MPC (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)	3.1%	ON	Yes-Gen			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)	54.2%	ON	Yes-Gen			
ORACEA (ORAL)	0.0%	OFF	No			
MINOCYCLINE CAPSULES (ORAL)	20.4%	ON	Yes-Gen			
VIBRAMYCIN SUSPENSION (ORAL)	0.0%	OFF	No			
DOXYCYCLINE HYCLATE CAPSULE (ORAL)	0.0%	OFF	No-Gen			
SOLODYN (ORAL)	0.1%	OFF	No			
DOXYCYCLINE HYCLATE TABLET (ORAL)	0.4%	ON	Yes-Gen			
DOXYCYCLINE MONOHYDRATE TABLET (ORAL)	21.2%	ON	Yes-Gen			
DOXYCYCLINE HYCLATE TABLET (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE HYCLATE TABLET DR (AG) (ORAL)	0.0%	NR	No-Gen			
DOXYCYCLINE MONOHYDRATE SUSPENSION (ORAL)	0.0%	OFF	No-Gen			
MINOCYCLINE ER (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE HYCLATE TABLET DR (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE MONOHYDRATE 40 MG CAPSULE (AG) (ORAL)	0.0%	OFF	No-Gen			
TETRACYCLINE (ORAL)	0.1%	OFF	No-Gen			
MINOCYCLINE TABLETS (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL)	0.0%	OFF	No-Gen			
DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL)	0.0%	OFF	No-Gen			
DORYX (ORAL)	0.0%	OFF	No			
DEMECLOXYCLINE (ORAL)	0.1%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second - Catherine Decker
  - All members were in favor of the motion
  - Motion Passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DELZICOL (ORAL)	0.6%	OFF	No			
SULFASALAZINE (ORAL)	18.1%	ON	Yes-Gen			
APRISO (ORAL)	15.3%	ON	Yes			
SULFASALAZINE DR (ORAL)	5.7%	ON	Yes-Gen			
LIALDA (ORAL)	43.2%	ON	Yes			
DIPENTUM (ORAL)	0.2%	OFF	No			
ASACOL HD (ORAL)	1.5%	OFF	No			
PENTASA (ORAL)	3.3%	OFF	No			
BALSALAZIDE (ORAL)	5.8%	ON	Yes-Gen			
GIAZO (ORAL)	0.0%	OFF	No			
MESALAMINE (ASACOL HD) (AG) (ORAL)	0.5%	NR	No-Gen			
UCERIS (ORAL)	1.8%	OFF	No			
CANASA (RECTAL)	2.6%	ON	Yes			
ROWASA (RECTAL)	1.1%	ON	Yes			
UCERIS (RECTAL)	0.0%	OFF	No			
MESALAMINE (RECTAL)	0.1%	OFF	No-Gen			
MESALAMINE KIT (RECTAL)	0.0%	OFF	No-Gen			

- Discussion: None
- Roseanne Barber made a motion to accept staff recommendations as presented.
  - Second - John Fangman
  - All members were in favor of the motion
  - Motion Passes